comparemela.com

Latest Breaking News On - Patrick nealon - Page 1 : comparemela.com

Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and

U.S. Food and Drug Administration (FDA) Guidance in Type C Meeting Supports Global Phase 3 Trial in Early-stage Choroidal MelanomaEnrollment Complete in Phase 2 Trial in Choroidal Melanoma Using Suprachoroidal Route of AdministrationBOSTON (BUSINESS WIRE) Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biot.

Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.